RUBINSTEIN JULIE sold $1.0M of ADPT
RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $28.46 ($27.57–$29.67, $1.01M total) across 5 trades over 2026-10-01 to 2026-10-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
While the transaction is small relative to the company's market cap, it may prompt short‑term price softness.
Market read
Primary source insider sale; modest size limits trading relevance.
What to watch
The 10b5‑1 plan indicates the sale was pre‑planned, reducing the informational value of the transaction.
Background
Form 4 filings disclose insider transactions; this filing reports a $1.0M sale by Adaptive Biotechnologies' President/COO.
Ticker impact
President and COO Julie Rubinstein sold $1.0M of ADPT shares via a 10b5‑1 plan, reducing her holdings to 377,802 shares.
likely slight downward pressure as the market prices in the insider sell
A C‑suite insider offloading over 35k shares signals potential concerns; the amount is modest but notable for a mid‑cap biotech.
Market effects
Minimal impact on the broader biotech sector; insider sales are routine and unlikely to shift sector sentiment.
None
None
Counterpoint
The sale could be purely portfolio rebalancing under a pre‑arranged plan, not a negative signal.
Key entities
- companyAdaptive Biotechnologies Corp
US‑listed biotech (ticker ADPT) whose President/COO sold shares.
- personJulie Rubinstein
President and COO of Adaptive Biotechnologies, insider seller.
